Meropenem/vaborbactam
| Combination of | |
|---|---|
| Meropenem | β-lactam antibiotic |
| Vaborbactam | β-lactamase inhibitor |
| Clinical data | |
| Trade names | Vabomere |
| Legal status | |
| Legal status |
|
| Identifiers | |
| KEGG | |
Meropenem/vaborbactam (trade name Vabomere) is a fixed dose combination drug for the treatment of urinary tract infections. It contains the β-lactam antibiotic meropenem and the β-lactamase inhibitor vaborbactam. In the United States, it is approved by the Food and Drug Administration for complicated urinary tract infections and pyelonephritis.[1]
References
- ↑ "FDA approves new antibacterial drug" (Press release). Food and Drug Administration. August 29, 2017.
This article is issued from
Wikipedia.
The text is licensed under Creative Commons - Attribution - Sharealike.
Additional terms may apply for the media files.